Singapore is one of Asia's most important biomedical and pharmaceutical hubs. Singapore has been able to attract both international and private investors who have driven the industry forward thanks to the government's Biomedical Sciences (BMS) project, which was launched in June 2000.

Singapore is the preferred place for enterprises to research and create new goods that better fulfil Asia’s healthcare demands since it is a major biomedical sciences cluster in the heart of Asia. Our pro-business environment, infrastructure, talent, and innovation ecosystem, as well as our proximity to the rest of Asia, all help businesses. Pharmaceutical and biotechnology companies have set up shop in Singapore to service patients from all over the world and connect with the booming Asian market, thanks to the city-large state’s pool of trained manpower, robust manufacturing capabilities, and dynamic research ecosystem.


Many best-in-class manufacturing facilities are located in Singapore, where a diverse range of goods, including small molecules, biologics, cell therapy, and medical nutrition, are launched and manufactured. GSK, Merck Sharp & Dohme (“MSD”), Pfizer, Novartis, Roche, Sanofi, AbbVie, and Amgen are among the top ten pharmaceutical corporations with production facilities in Singapore.


Singapore has made significant investments in infrastructure to assist pharmaceutical businesses in establishing manufacturing operations in the city-state, including ready-built facilities and innovative partnerships.

Start-up Ecosystem Growing

Singapore is building on the foundation of Big Pharma businesses to strengthen the biotech community through finance and commercialization interventions in order to generate a globally competitive and inventive biomedical sector.

In 2018, the Singapore government established the National Research Fund (“NRF”)-Temasek IP commercialization vehicle to assist Singapore-based biotechs in their commercialization activities. The fund co-invests in start-ups whose business models are based on intellectual property developed through publically supported research.

Developing the digital health ecosystem

Working with the business sector, Singapore’s public healthcare system is also pioneering patient-centered digital innovation. Companies will be able to innovate and commercialize innovative solutions for clinical needs across Asian markets, starting with Singapore, as a result of these relationships. In Singapore, we’ve seen the creation of a sizable digital health sector, which now employs over 2,200 people and includes close to 250 enterprises. Singapore has grown its digital health ecosystem by using the natural capabilities of its public innovation and healthcare institutions, as well as the breadth and depth of existing industry sectors.

What Bluebox can do for you?

We assist our clients in adapting their business practices to changing standards as they deal with the difficulties of today and tomorrow. As trusted advisors to businesses, we strive to provide innovative solutions to the wide spectrum of difficulties that the healthcare industry faces. To provide a fresh viewpoint and innovative ideas, we draw on our considerable expertise in both the commercial and governmental sectors. Professionals from our firms are able to share their expertise and contribute to the development of new ideas.
Scroll to Top